 Ajay Major
Concepts (225)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 7 | 2025 | 125 | 3.890 |
Why?
| | Hematologic Neoplasms | 3 | 2025 | 158 | 2.310 |
Why?
| | Multiple Myeloma | 9 | 2024 | 253 | 1.970 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 14 | 2024 | 1695 | 1.910 |
Why?
| | Hodgkin Disease | 5 | 2025 | 139 | 1.770 |
Why?
| | Lymphoma, Non-Hodgkin | 2 | 2023 | 88 | 1.530 |
Why?
| | Medical Oncology | 5 | 2024 | 290 | 1.440 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2022 | 614 | 1.420 |
Why?
| | Antibodies, Bispecific | 2 | 2025 | 54 | 1.040 |
Why?
| | Neoplasms | 4 | 2022 | 2666 | 0.970 |
Why?
| | Immunotherapy, Adoptive | 3 | 2023 | 324 | 0.870 |
Why?
| | Patient Reported Outcome Measures | 2 | 2024 | 403 | 0.830 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2024 | 1060 | 0.820 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2025 | 252 | 0.790 |
Why?
| | Lymphoproliferative Disorders | 2 | 2023 | 55 | 0.770 |
Why?
| | Plasma Exchange | 1 | 2021 | 14 | 0.750 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 15 | 0.740 |
Why?
| | Quality of Life | 5 | 2025 | 2870 | 0.720 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2022 | 129 | 0.720 |
Why?
| | Psychosocial Support Systems | 1 | 2021 | 13 | 0.710 |
Why?
| | Vaccination | 2 | 2021 | 1398 | 0.710 |
Why?
| | Lymphoma, B-Cell | 2 | 2022 | 107 | 0.710 |
Why?
| | Cyclophosphamide | 4 | 2024 | 251 | 0.710 |
Why?
| | Dexamethasone | 7 | 2024 | 377 | 0.700 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 31 | 0.690 |
Why?
| | Hospice Care | 1 | 2024 | 201 | 0.690 |
Why?
| | Terminal Care | 1 | 2024 | 224 | 0.680 |
Why?
| | Internship and Residency | 2 | 2021 | 1131 | 0.680 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1047 | 0.670 |
Why?
| | Humans | 57 | 2025 | 137514 | 0.650 |
Why?
| | Lymphoma, Follicular | 1 | 2019 | 40 | 0.630 |
Why?
| | Drug Costs | 1 | 2020 | 106 | 0.630 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2019 | 98 | 0.610 |
Why?
| | Internal Medicine | 1 | 2021 | 254 | 0.590 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 115 | 0.580 |
Why?
| | Brain Neoplasms | 2 | 2017 | 1241 | 0.560 |
Why?
| | Adrenal Insufficiency | 1 | 2018 | 32 | 0.560 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2017 | 20 | 0.540 |
Why?
| | Oncologists | 1 | 2017 | 36 | 0.540 |
Why?
| | Etoposide | 3 | 2024 | 157 | 0.530 |
Why?
| | Vincristine | 3 | 2024 | 116 | 0.530 |
Why?
| | Central Nervous System Neoplasms | 3 | 2024 | 158 | 0.520 |
Why?
| | Neoplasm, Residual | 4 | 2024 | 133 | 0.520 |
Why?
| | Immunocompromised Host | 1 | 2018 | 203 | 0.510 |
Why?
| | Mental Health Services | 1 | 2021 | 415 | 0.500 |
Why?
| | Medicare | 2 | 2023 | 747 | 0.490 |
Why?
| | Lymphoma | 3 | 2023 | 207 | 0.490 |
Why?
| | Antineoplastic Agents | 2 | 2025 | 2145 | 0.490 |
Why?
| | Doxorubicin | 3 | 2024 | 368 | 0.470 |
Why?
| | Empathy | 1 | 2017 | 180 | 0.470 |
Why?
| | Aged | 20 | 2025 | 23798 | 0.450 |
Why?
| | Cancer Survivors | 1 | 2019 | 280 | 0.450 |
Why?
| | Health Personnel | 1 | 2021 | 699 | 0.450 |
Why?
| | Mental Health | 1 | 2021 | 724 | 0.450 |
Why?
| | Students, Medical | 2 | 2021 | 341 | 0.430 |
Why?
| | Rituximab | 3 | 2024 | 178 | 0.430 |
Why?
| | Hematology | 3 | 2024 | 20 | 0.430 |
Why?
| | Curriculum | 1 | 2020 | 980 | 0.420 |
Why?
| | Health Services Accessibility | 1 | 2021 | 976 | 0.420 |
Why?
| | Bullying | 1 | 2014 | 41 | 0.410 |
Why?
| | Transplantation, Autologous | 3 | 2023 | 238 | 0.410 |
Why?
| | Aged, 80 and over | 10 | 2025 | 7593 | 0.410 |
Why?
| | Middle Aged | 19 | 2025 | 33355 | 0.390 |
Why?
| | Mental Disorders | 1 | 2021 | 1083 | 0.380 |
Why?
| | Physicians | 1 | 2021 | 904 | 0.380 |
Why?
| | Oligopeptides | 2 | 2024 | 273 | 0.380 |
Why?
| | Treatment Outcome | 10 | 2025 | 10821 | 0.380 |
Why?
| | Prednisone | 2 | 2024 | 245 | 0.380 |
Why?
| | Healthcare Disparities | 1 | 2018 | 651 | 0.380 |
Why?
| | Prognosis | 6 | 2024 | 4031 | 0.370 |
Why?
| | Pediatrics | 1 | 2020 | 1123 | 0.370 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2017 | 683 | 0.360 |
Why?
| | Delivery of Health Care | 1 | 2018 | 948 | 0.360 |
Why?
| | Faculty, Medical | 1 | 2014 | 283 | 0.350 |
Why?
| | Education, Medical | 1 | 2014 | 260 | 0.340 |
Why?
| | Male | 22 | 2025 | 67718 | 0.330 |
Why?
| | Adult | 16 | 2025 | 37821 | 0.320 |
Why?
| | Skin Neoplasms | 1 | 2017 | 853 | 0.310 |
Why?
| | Public Health Surveillance | 2 | 2020 | 80 | 0.310 |
Why?
| | Young Adult | 9 | 2025 | 13243 | 0.310 |
Why?
| | Information Dissemination | 2 | 2022 | 218 | 0.300 |
Why?
| | Female | 20 | 2025 | 73162 | 0.280 |
Why?
| | Neoplasm Staging | 3 | 2024 | 1377 | 0.270 |
Why?
| | Retrospective Studies | 9 | 2025 | 15628 | 0.260 |
Why?
| | Fatal Outcome | 2 | 2017 | 305 | 0.260 |
Why?
| | Databases, Factual | 2 | 2022 | 1351 | 0.240 |
Why?
| | Platelet Factor 4 | 2 | 2022 | 35 | 0.230 |
Why?
| | Disease Management | 2 | 2018 | 625 | 0.220 |
Why?
| | Genital Neoplasms, Female | 1 | 2025 | 88 | 0.220 |
Why?
| | Methotrexate | 2 | 2023 | 260 | 0.220 |
Why?
| | Antibodies, Monoclonal | 2 | 2024 | 1428 | 0.220 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 16 | 0.220 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2494 | 0.210 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2025 | 191 | 0.210 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2023 | 82 | 0.200 |
Why?
| | Azacitidine | 1 | 2024 | 141 | 0.200 |
Why?
| | Geriatrics | 1 | 2024 | 88 | 0.200 |
Why?
| | Hospices | 1 | 2024 | 87 | 0.200 |
Why?
| | Time-to-Treatment | 1 | 2024 | 205 | 0.200 |
Why?
| | Education, Medical, Graduate | 3 | 2022 | 481 | 0.200 |
Why?
| | Melphalan | 1 | 2022 | 35 | 0.200 |
Why?
| | Bortezomib | 1 | 2022 | 54 | 0.190 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2024 | 228 | 0.190 |
Why?
| | Watchful Waiting | 1 | 2022 | 80 | 0.190 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2022 | 35 | 0.190 |
Why?
| | Amyloidosis | 1 | 2022 | 44 | 0.190 |
Why?
| | Africa | 1 | 2022 | 109 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 99 | 0.180 |
Why?
| | Platelet Count | 1 | 2021 | 86 | 0.180 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2022 | 94 | 0.180 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 21 | 0.180 |
Why?
| | Health Occupations | 1 | 2020 | 33 | 0.170 |
Why?
| | Sirolimus | 1 | 2022 | 275 | 0.170 |
Why?
| | Fellowships and Scholarships | 2 | 2022 | 306 | 0.170 |
Why?
| | Home Care Services | 1 | 2024 | 254 | 0.170 |
Why?
| | Sulfonamides | 1 | 2024 | 513 | 0.170 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2025 | 252 | 0.170 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2022 | 366 | 0.170 |
Why?
| | Frailty | 1 | 2023 | 169 | 0.160 |
Why?
| | Thrombocytopenia | 1 | 2022 | 199 | 0.160 |
Why?
| | Blood Coagulation Disorders | 1 | 2022 | 173 | 0.160 |
Why?
| | Survivorship | 1 | 2020 | 49 | 0.160 |
Why?
| | Botulism | 1 | 2019 | 6 | 0.160 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 414 | 0.150 |
Why?
| | Personal Satisfaction | 1 | 2021 | 211 | 0.150 |
Why?
| | Medical Informatics | 1 | 2020 | 100 | 0.150 |
Why?
| | Program Development | 1 | 2021 | 366 | 0.150 |
Why?
| | Heroin Dependence | 1 | 2019 | 33 | 0.150 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5772 | 0.150 |
Why?
| | SEER Program | 1 | 2019 | 218 | 0.150 |
Why?
| | Neoplasm Grading | 1 | 2019 | 308 | 0.150 |
Why?
| | Education, Medical, Undergraduate | 1 | 2021 | 186 | 0.150 |
Why?
| | Pandemics | 3 | 2022 | 1619 | 0.150 |
Why?
| | Artificial Intelligence | 1 | 2021 | 275 | 0.150 |
Why?
| | Needs Assessment | 1 | 2020 | 368 | 0.140 |
Why?
| | Risk Factors | 4 | 2024 | 10356 | 0.140 |
Why?
| | Social Media | 1 | 2020 | 157 | 0.140 |
Why?
| | Substance Abuse, Intravenous | 1 | 2019 | 114 | 0.140 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2024 | 620 | 0.140 |
Why?
| | Immunosuppressive Agents | 2 | 2023 | 891 | 0.140 |
Why?
| | Prednisolone | 1 | 2017 | 83 | 0.130 |
Why?
| | Symptom Assessment | 1 | 2018 | 126 | 0.130 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 45 | 0.130 |
Why?
| | Narration | 1 | 2017 | 58 | 0.130 |
Why?
| | Program Evaluation | 1 | 2021 | 892 | 0.130 |
Why?
| | Vaccines | 1 | 2022 | 411 | 0.130 |
Why?
| | Research | 1 | 2020 | 446 | 0.130 |
Why?
| | Machine Learning | 1 | 2021 | 496 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 892 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2022 | 807 | 0.130 |
Why?
| | Immunotherapy | 1 | 2021 | 647 | 0.120 |
Why?
| | Adaptation, Psychological | 1 | 2021 | 653 | 0.120 |
Why?
| | Survivors | 1 | 2019 | 489 | 0.120 |
Why?
| | Pilot Projects | 1 | 2021 | 1703 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2018 | 1263 | 0.120 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2017 | 235 | 0.120 |
Why?
| | Burnout, Professional | 1 | 2022 | 442 | 0.120 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1241 | 0.120 |
Why?
| | Anxiety | 1 | 2021 | 1041 | 0.110 |
Why?
| | Adolescent | 4 | 2025 | 21555 | 0.100 |
Why?
| | Attitude of Health Personnel | 1 | 2021 | 1169 | 0.100 |
Why?
| | Clinical Competence | 1 | 2020 | 1093 | 0.100 |
Why?
| | Mutation | 1 | 2024 | 3964 | 0.100 |
Why?
| | United States | 4 | 2025 | 14696 | 0.100 |
Why?
| | Cytokines | 1 | 2021 | 2095 | 0.100 |
Why?
| | Child | 3 | 2022 | 22037 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2021 | 1115 | 0.100 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1999 | 0.100 |
Why?
| | Age Factors | 1 | 2020 | 3301 | 0.100 |
Why?
| | Registries | 1 | 2020 | 2021 | 0.090 |
Why?
| | Cell Differentiation | 1 | 2019 | 1979 | 0.090 |
Why?
| | Depression | 1 | 2021 | 1408 | 0.090 |
Why?
| | Prevalence | 1 | 2018 | 2719 | 0.090 |
Why?
| | Colorado | 1 | 2021 | 4521 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2017 | 1040 | 0.080 |
Why?
| | Recurrence | 2 | 2024 | 1060 | 0.070 |
Why?
| | Antigens, CD20 | 1 | 2025 | 29 | 0.060 |
Why?
| | Nigeria | 1 | 2025 | 22 | 0.060 |
Why?
| | Maintenance Chemotherapy | 1 | 2024 | 35 | 0.060 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2024 | 9 | 0.060 |
Why?
| | Lymphoma, T-Cell | 1 | 2024 | 25 | 0.060 |
Why?
| | Withholding Treatment | 1 | 2024 | 76 | 0.050 |
Why?
| | Thalidomide | 1 | 2024 | 40 | 0.050 |
Why?
| | Cytarabine | 1 | 2023 | 61 | 0.050 |
Why?
| | Cell Transplantation | 1 | 2023 | 37 | 0.050 |
Why?
| | Imides | 1 | 2022 | 11 | 0.050 |
Why?
| | Proteasome Inhibitors | 1 | 2022 | 45 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2024 | 233 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5427 | 0.050 |
Why?
| | Frail Elderly | 1 | 2023 | 126 | 0.050 |
Why?
| | Biotin | 1 | 2022 | 28 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 167 | 0.050 |
Why?
| | Academic Medical Centers | 1 | 2025 | 498 | 0.050 |
Why?
| | Injections, Spinal | 1 | 2022 | 108 | 0.050 |
Why?
| | Education, Premedical | 1 | 2021 | 5 | 0.050 |
Why?
| | Blogging | 1 | 2021 | 6 | 0.050 |
Why?
| | Geriatric Assessment | 1 | 2023 | 214 | 0.050 |
Why?
| | Blood Component Transfusion | 1 | 2022 | 84 | 0.050 |
Why?
| | Professionalism | 1 | 2021 | 19 | 0.040 |
Why?
| | Polymerase Chain Reaction | 1 | 2024 | 1061 | 0.040 |
Why?
| | Central Nervous System | 1 | 2023 | 261 | 0.040 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 446 | 0.040 |
Why?
| | Heparin | 1 | 2022 | 259 | 0.040 |
Why?
| | Plasma | 1 | 2022 | 213 | 0.040 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 806 | 0.040 |
Why?
| | Lymphocytes | 1 | 2022 | 395 | 0.040 |
Why?
| | Societies, Medical | 1 | 2024 | 820 | 0.040 |
Why?
| | Writing | 1 | 2021 | 95 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2021 | 407 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2023 | 414 | 0.040 |
Why?
| | Dysphonia | 1 | 2019 | 15 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2022 | 493 | 0.040 |
Why?
| | Blood Transfusion | 1 | 2022 | 324 | 0.040 |
Why?
| | Drug Contamination | 1 | 2019 | 52 | 0.040 |
Why?
| | Paraplegia | 1 | 2019 | 60 | 0.040 |
Why?
| | Muscle Weakness | 1 | 2019 | 87 | 0.040 |
Why?
| | Diagnostic Errors | 1 | 2019 | 171 | 0.040 |
Why?
| | Biomedical Research | 1 | 2024 | 689 | 0.030 |
Why?
| | Deglutition Disorders | 1 | 2019 | 143 | 0.030 |
Why?
| | Dyspnea | 1 | 2019 | 251 | 0.030 |
Why?
| | Hepatitis C, Chronic | 1 | 2019 | 164 | 0.030 |
Why?
| | Incidence | 1 | 2023 | 2792 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 299 | 0.030 |
Why?
| | Risk Assessment | 1 | 2023 | 3439 | 0.030 |
Why?
| | Cohort Studies | 1 | 2023 | 5730 | 0.020 |
Why?
|
|
Major's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|